Quantcast

Latest Growth hormone treatment Stories

2011-07-11 06:30:00

NES-ZIONA, Israel, July 11, 2011 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE Amex: PBTH), today announced that it has received a notice of allowance from the U.S. Patent and Trademark Office (PTO) for a patent application covering the company's CTP platform, which has the potential to extend the duration of activity of virtually all therapeutic proteins. The allowed claims cover CTP-modified compositions of a wide array of classes of therapeutic proteins, including hormones, high affinity...

2011-07-03 00:01:48

Diplomat Specialty Pharmacy, the nation's largest privately held specialty pharmacy company, revealed the results of its annual patient satisfaction survey today. The survey, conducted by Gartner & Associates LLC in May 2011, reaffirms Diplomat's industry leading patient satisfaction rates. Key survey findings reflect: "¢ 99% of customer respondents were satisfied overall with Diplomat "¢ 98% indicated that Diplomat meets their expectations "¢ 90% indicated that...

2011-06-30 15:05:00

FLINT, Mich., June 30, 2011 /PRNewswire/ -- Diplomat Specialty Pharmacy, the nation's largest privately held specialty pharmacy company, revealed the results of its annual patient satisfaction survey today. The survey, conducted by Gartner & Associates LLC in May 2011, reaffirms Diplomat's industry leading patient satisfaction rates. Key survey findings reflect: 99% of customer respondents were satisfied overall with Diplomat 98% indicated that Diplomat meets their expectations 90%...

2011-06-29 17:22:00

PHILADELPHIA, June 29, 2011 /PRNewswire/ -- This evening, Novo Nordisk awarded sponsorships totaling $85,000 to four Philadelphia-based community organizations to educate local communities and raise awareness of diabetes to reduce the risk for long-term diabetes related complications. The sponsorships are part of the Novo Nordisk Community Care program, which aims to partner with local organizations to promote enduring, sustainable change at the local level for people living with...

2011-06-20 06:30:00

NES-ZIONA, Israel, June 20, 2011 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE Amex: PBTH), today announced that its paediatric investigation plan for clinical development of its long-acting human growth hormone (hGH-CTP) has been accepted for review by the Paediatric Committee of the European Medicines Agency (EMA). Following promising efficacy and safety interim results in its ongoing Phase II trial of hGH-CTP in growth hormone-deficient adults, PROLOR is now actively pursuing development...

2011-06-13 06:30:00

NES-ZIONA, Israel, June 13, 2011 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE Amex: PBTH), today announced that the U.S. Patent and Trademark Office (PTO) has allowed a new patent for the company's veterinary version of its long-acting CTP-enhanced non-human growth hormone (NhGH-CTP). The patent covers the composition of PROLOR's proprietary pharmaceutical non-human growth hormone as well as certain associated methods of use for veterinary applications. "This new patent covering...

2011-06-06 06:00:00

NES-ZIONA, Israel, June 6, 2011 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE Amex: PBTH) today reported positive results from a comparative animal study of its long-acting anti-obesity drug candidate oxyntomodulin (OXY-RPEG). The study measured the potential therapeutic effect of OXY-RPEG injected once or twice weekly as measured by weight loss and reduction in food intake compared with oxyntomodulin injected twice daily. It was conducted using a state-of-the-art animal model specifically...

2011-06-06 05:00:00

NEW YORK and JERUSALEM, June 6, 2011 /PRNewswire/ -- Chiasma, Inc., a privately held biopharma company, presented pharmacology results from clinical studies at the 12th International Pituitary Congress showing that Octreolin, a proprietary investigational new oral formulation of octreotide, demonstrated a consistent pharmacokinetic (PK) profile similar to that of subcutaneously injected octreotide acetate. Most important, the data illustrated that Octreolin reduced growth hormone (GH)...

2011-05-25 07:00:00

SAN DIEGO, May 25, 2011 /PRNewswire/ -- Ambrx Inc. today announced that data from a Phase 1/2 study, published online ahead of print on May 16 by Proceedings of the National Academy of Sciences, demonstrate the safety, efficacy and superior dosing frequency of ARX201, a sustained action human growth hormone, compared to therapy with native hormone. The study evaluated adult GH-deficient (AGHD) patients treated with ARX201, which was generated with Ambrx's ReCODE(TM) technology. ARX201...

2011-05-16 20:27:38

Scientists at the Sahlgrenska Academy have discovered an explanation of how stroke patients can achieve better recovery. A hormone that is associated with the growth hormone system has proved to benefit recovery during the later phases of rehabilitation after a stroke. Insulin-like growth factor I, IGF-I, is a hormone that is found in the blood and contributes to, among other things, growth and bone mass. The levels of this hormone are higher in people who exercise regularly and those with...


Word of the Day
glogg
  • Scandinavian punch made of claret and aquavit with spices and raisins and orange peel and sugar.
This word comes from the Swedish 'glogg,' which is an alteration of 'glodgat,' mulled (wine).
Related